Indeed, we report that diclofenac—a well-studied and clinically safe and approved drug—restrains the glycolytic phenotype of BRAF-mutated papillary and anaplastic thyroid carcinoma cells, opening new relevant clinical perspectives for these tumours. Here, BRAF is linked to neoplasm.